A new indication for omalizumab is prompting clinicians to adjust their approach to oral food challenges, but experts ...

A clinical trial has found that the medication omalizumab, marketed as Xolair, treated multi-food allergy more effectively than oral immunotherapy (OIT) in people with allergic reactions to very ...

SAN DIEGO -- Omalizumab (Xolair) injections outperformed oral immunotherapy (OIT) in increasing tolerance among children with multi-food allergy, largely because many patients couldn't tolerate ...

Omalizumab, currently used to treat asthma, has been shown to substantially reduce the risk of potentially life-threatening reactions in people aged one and older with multiple common food ...

Omalizumab was found to be more effective than multi-allergen oral immunotherapy (OIT) in reducing allergic reactions in patients with 1 or more food allergies, according to results from Stage 2 ...

Omalizumab works by binding to the allergy-causing antibody called immunoglobulin E in the blood and preventing it from arming key immune cells responsible for allergic reactions.

The Food and Drug Administration (FDA) has approved Omlyclo ® (omalizumab-igec), the first interchangeable biosimilar to Xolair ® (omalizumab).. Omlyclo, formerly known as CT-P39, is an anti ...

Omalizumab is also considered unique, as it is safe for children as young as 1-year-olds. Currently, there is only one additional FDA-approved treatment for food allergy ...

EAACI: Dupixent demonstrated superiority over Xolair (omalizumab) in chronic rhinosinusitis with nasal polyps in patients with coexisting asthma in first-ever presented phase 4 head-to-head ...

A systematic review of the effectiveness of omalizumab in daily clinical practice highlighted data for its high degree of effectiveness and positive safety profile in daily clinical practice. "It ...

During the first period, study participants (N=619) were randomly assigned to receive omalizumab-igec 300mg, Xolair 300mg, omalizumab-igec 150mg, or Xolair 150mg for 12 weeks.